Mfg News: Roche, Fosun Pharma & Intas
A roundup of manufacturing news from Roche, Fosun Pharma and Intas. Highlights below.
* Roche To Divest Biomanufacturing Site in Vacaville, California
* Fosun Pharma To Build $106-M Drug-Product Mfg Facility in Africa
* FDA Issues Import Alert to Intas
Roche To Divest Biomanufacturing Site in Vacaville, California
Roche has announced plans to divest its biomanufacturing facility in Vacaville, California, as part of a broader strategy to evolve its manufacturing capabilities in line with future pipeline requirements.
The Vacaville site has more than 427,000 square feet of space devoted to manufacturing, maintenance, laboratories, office space, and warehousing, and specializes in large-scale production of biologics.
The company said it will initiate a process of finding a buyer for the site, and a decision will be announced when it does.
Source: Roche
Fosun Pharma To Build $106-M Drug-Product Mfg Facility in Africa
Shanghai Fosun Pharmaceutical, a Shanghai-based bio/pharmaceutical company, has announced a partnership with the International Finance Corporation (IFC), a member of the World Bank Group, to help the company build a pharmaceutical production facility and distribution hub in Abidjan, Côte d’Ivoire, West Africa.
Under the partnership, IFC will provide subsidiaries of Fosun Pharma with two loans totaling EUR 50 million ($54 million) to support the construction of a manufacturing site near Abidjan to produce anti-malaria drugs and anti-bacterial medicines. The building of the facility, which will take place in three phases, is expected to have a capacity of 5 billion tablets annually after Phase 3 completion.
Source: Shanghai Fosun Pharmaceutical
FDA Issues Import Alert to Intas
The US Food and Drug Administration (FDA) has issued an import alert to Intas Pharmaceuticals, an Ahmedabad, Gujarat, India-based bio/pharmaceutical company, for products manufactured at the company’s drug-product manufacturing facility in Taluka, Sanand, India. The import alert does not apply to 16 injectable drug products and nine oral solid-dosage drug products currently determined to be in shortage by the FDA. The import alert follows an FDA inspection of the facility from November 22 to December 2, 2022, and applies until the company can demonstrate that the drugs manufactured at this site and intended for the US market are in compliance with cGMP.
